Greeting Greeting


We would like to express our ceaseless gratitude to our customers and partners for the trust and love they display for Samyang Holdings Biopharmaceuticals Division

Samyang Holdings Biopharmaceuticals Division started off as a Samyang Corporation’s Pharmaceutical Division. In 2011, Samyang Biopharmaceuticals was established as a split-off of Samyang Corporation’s Pharmaceutical Division, and in 2021, in order to stably procure funding sources required for mid and long-term investments, Samyang Biopharmaceuticals was absorbed by Samyang Holdings. Currently, Samyang Holdings Biopharmaceuticals Division is providing anticancer drugs and surgical suture to around 150 clients in 45 different countries.

Based on our future vision: 'Value Generating Pharma Company‘, we have been focusing all our R&D and innovative capabilities on the field of medical biotechnology that is a core area of the 21st century.
To achieve this vision, our Pharmaceutical Business will expand their portfolio of the DDS-based anticancer drug and develop innovative global new drugs through discovery of drug candidates in the U.S.
Furthermore, the MD division will strengthen the competitiveness of the existing suture business through continuous growth in its global core market and subsequently expand the new portfolio on absorbable materials.

In addition, we completed the construction of Samyang Discovery Center in Pangyo Techno Valley in 2016 and established Samyang Biopharm USA Inc. in 2018. This establishment will serve as a strong foundation for Samyang Holdings Biopharmaceuticals Division to thrive globally as an innovative R&D-based global pharmaceutical company.

Thank you.

THead of Samyang Holdings biopharmaceutical division / Lee Young-Joon